Return
Transition from intermediate to late AMD and associated changes in vision by two years in a multicentre cohort study in Europe- INTERCEPT-AMD Report 3
S
I
J
Y
M
L
H
S
E
J
L
R
H
A
B
S
S
DOI:10.1038/s41433-026-04759-9.png)
Abstract
En 中文
The aim was to evaluate the incidence of late AMD in eyes with intermediate AMD (iAMD) over two years. In this multicentre cohort study, participants with iAMD were classified as: (i) iAMD without incomplete retinal pigment epithelium or outer retinal atrophy (iRORA) or subretinal drusenoid deposits (SDD); (ii) iAMD with SDD with no iRORA; (iii) iAMD with iRORA with no SDD and (iv) iAMD with iRORA and SDD. Factors associated with the incidence of late AMD were analysed using an interval-censored Weibull parametric proportional hazards model. 983 eyes from 805 participants were analysed. Model-based cumulative incidence at nominal 2 years was 13.1% (95% CI 10.8–15.6%) for late AMD, 7.6% (95% CI 5.9–9.3%) for nAMD as the cause and 5.5% (95% CI 4.1–7.3%) for cRORA as the cause. Participants aged 75–84 (adjusted HR [aHR] 1.66, 95% CI 1.13–2.46; P = 0.01), 85 years+ (aHR 2.48, 95% CI 1.49–4.15; P = 0.001), presence of iRORA (aHR 1.50, 95% CI 1.05–2.16; P = 0.03), fellow-eye nAMD (aHR 3.23, 95% CI 2.04–5.12; P < 0.001) and BRVA 70–79 (vs 80 or better ETDRS letters: aHR 1.65, 95% CI 1.09–2.49; P = 0.02) had increased hazard of late AMD. Eyes that transitioned to neovascular AMD (nAMD) by 2 years (within tolerance window) displayed the greatest loss in BRVA compared to other phenotypes (–6.01 letters, SD 11.35). Approximately 13% of eyes with iAMD progressed to late AMD within 2 years. Eyes that transitioned to nAMD experienced the greatest loss in BRVA.
Journal
IF:
3.2
Papers:
1.3K
Citations:
1.7W

